Interferon-β1a: A once-weekly immunomodulatory treatment for patients with multiple sclerosis

Expert Review of Clinical Immunology

Volumn 2, Issue 5, 2006, Pages 691-704

  Philip Kinkel, R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Disease modifying agents; Interferon 1a; Multiple sclerosis

Indexed keywords

EID: 77952830010     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2.5.691     Document Type: Article

References (76)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl. J. Med. 343, 938-952 (2000).
2. Zivadinov R, Rudick RA, De Masi R et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57(7), 1239-1247 (2001). (Pubitemid 32947383)
3. Lucchinetti CF, Bruck W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707-717 (2000). (Pubitemid 30390191)
4. Barnett MH, Prineas JW. Relapsíng-remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55, 458-468 (2004). (Pubitemid 38391962)
5. Kutzelnigg A, Lucchinetti CF, Stadelmann C et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705-2712 (2005). (Pubitemid 41552953)
6. Miller DH, Albert PS, Barkhof F et al Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. VS National MS Society Task Force. Ann. Neurol 39, 6-16 (1996). (Pubitemid 26052212)
7. Fillipi M, Falini A, Arnold D et al. Magnetic resonance techniques for in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group. J. Mag. Reson. Imag. 21, 669-675 (2005). (Pubitemid 40770857)
8. Stone LA, Albert PS, Smith ME et al Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 45(10), 1808-1814 (1995). (Pubitemid 27122949)
9. Wingerchuk DM, Noseworthy JH, Weinshenker BG. Clinical outcome measures and rating scales in multiple sclerosis trials. Mayo Clin. Proc. 72, 1070-1079 (1997). (Pubitemid 27500610)
10. Rudick RA, Fisher E, Lee J-C, Simon J, Jacobs L, Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 53, 1698-1704(1999). (Pubitemid 29530342)
11. Kappos L, Moeri D, Radue EW et al Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 353(9157), 964-969 (1999). (Pubitemid 29132605)
12. Molyneux PD, Filippi M, Barkhof F et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann. Neurol. 43, 332-339 (1998). (Pubitemid 28113596)
13. Frank JA, Stone LA, Smith ME et al Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann. Neurol. 36(Suppl.), S86-S90 (1994). (Pubitemid 24220848)
14. van Walderveen MAA, Barkhof F, Hommes OR et al Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spinecho images. Neurology 45(9), 1687-1690 (1995).
15. Brex PA, Ciccarelli O, O'Riordan JI et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl J. Med. 346(3), 158-164 (2002). (Pubitemid 34438881)
16. Rudick RA, Cutter GR, Baier M et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult. Scler. 11, 626-634 (2005). (Pubitemid 41685131)
17. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult. Scler. 5(4), 244-250 (1999). (Pubitemid 29405620)
18. Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systemic review. Arch. Intern. Med. 162, 2161-2169(2002). (Pubitemid 35231583)
19. The PRISMS (Prevention of Relapses and disability by Interferon β-la Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-la in relapsing/remitting multiple sclerosis. Lancet 352(9139), 1498-1504 (1998).
20. Jacobs LD, Cookfair DL, Rudick RA et al Intramuscular interferon β-la for disease progression in relapsing multiple sclerosis. Ann. Neurol 39(3), 285-294 (1996). (Pubitemid 26100751)
21. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Results of a Phase III multicenter, double-blind, placebo-controlled trial. Neurology 45, 1268-1276 (1995).
22. IFNβ Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4), 655-661 (1993).
23. Polman CH, Uitdehaag BMJ. New and emerging treatment options for multiple sclerosis. Lancet Neurol. 2(9), 563-566 (2003). (Pubitemid 36994996)
24. Dupont SA, Goelz S, Goyal J, Green M. Mechanisms for regulation of cellular responsiveness to human IFN-β la. J. Interferon Cytokine Res. 22, 491-501 (2002). (Pubitemid 34579552)
25. Lau JF, Horvath CM. Mechanisms of type I interferon cell signaling and STAT-mediated transcriptional responses. Mt Sinai J. Med. 69(3), 156-168 (2002). (Pubitemid 34525049)
26. Kozovska ME, Hong J, Zang YCQ et al. Interferon β induces T-helper 2 immune deviation in MS. Neurology 53, 1692-1697(1999). (Pubitemid 29530341)
27. Rudick RA, Ransohoff RM, Lee JC et al. In vivo effects of interferon β-la on immunosuppressive cytokines in multiple sclerosis. Neurology 50, 1294-1300 (1998a). (Pubitemid 28240342)
28. Byrnes AA, McArthur JC, Karp CL. Interferon-β therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann. Neurol. 51, 165-174 (2002). (Pubitemid 34111438)
29. Koike F, Satoh J, Miyake S et al. Microarray analysis identifies interferon β-regulated genes in multiple sclerosis. J. Neuroimmunol 139, 109-118 (2003). (Pubitemid 36694397)
30. Zang YC, Haider JB. Samanta AK, Hong J. Rivera VM, Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-la by interferon-β. J Neuroimmunol 112(1, 2), 174-180 (2001).
31. Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon β. Neurology 49, 1111-1116 (1997). (Pubitemid 27456096)
32. AVONEX® (package insert). Biogen Idec, Inc., Cambridge, MA, USA (2005).
33. Phillips JT, Rice G, Frohman E et al A multicenter, open-label, Phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin. Ther. 26, 511-521 (2004). (Pubitemid 38586452)
34. Alam J, McAllister A, Scaramucci J, Jones W, Rogge M. Pharmacokinetics and pharmacodynamics of interferon β-la (IFNβ-la) in healthy volunteers after intravenous, subcutaneous or intramuscular administration. Clin. Drug. Invest. 14(1), 35-43 (1997a). (Pubitemid 27338835)
35. Alam J, Goelz S, Rioux P et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon β-la products administered intramuscularly in healthy male and female volunteers. Pharmaceut. Res. 14, 546-549 (1997b). (Pubitemid 27205021)
36. Munafo A, Trinchard-Lugan I, Nguyen TXQ, Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon β-la after intramuscular and subcutaneous administration. Eur. J. Neurol. 5(2), 187-193 (1998). (Pubitemid 28142571)
37. Runkel L, Meier W, Pepinsky RB et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm. Res. 15(4), 641-649 (1998). (Pubitemid 28214960)
38. Bagnato F, Pozzilli C, Scagnolari C et al. A one-year study on the pharmacodynamic profile of interferon-β la in MS. Neurology 58, 1409-1411 (2002). (Pubitemid 34507172)
39. Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNβ bioactivity. Detection of antibody-mediated decreased bioactivity (ADB). Neurology 61(Suppl. 5), S24-S26 (2003). (Pubitemid 37386116)
40. Bertolotto A, Gilli F, Sala A et al. Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J. Immunol Methods 256, 141-152 (2001). (Pubitemid 32769923)
41. Jacobs LD, Beck RW, Simon JH et al.; CHAMPS Study Group. Intramuscular interferon β-la therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med. 343, 898-904 (2000).
42. CHAMPIONS Study Group. IM interferon β-la delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66(5), 678-684 (2006).
43. Clanet M, Radue EW, Kappos L et al A randomized, double-blind, dose-comparison study of weekly interferon β-la in relapsing MS. Neurology 59, 1507-1517 (2002). (Pubitemid 35387054)
44. Panitch H, Goodin DS, Francis G et al, for the EVIDENCE (Evidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon β-la treatment regimens in MS. The EVIDENCE trial. Neurology 59, 1496-1506(2002). (Pubitemid 35387053)
45. Cohen JA, Cutter GR, Fischer JS et al, for the IMPACT Investigators. Benefit of interferon β-la on MSFC progression in secondary progressive MS. Neurology 59, 679-687 (2002).
46. Herndon RM, Rudick RA, Munschauer FE et al. Eight-year immunogenicity and safety of interferon β-la-Avonex® treatment in patients with multiple sclerosis. Mult. Scler. 11, 1-11(2005).
47. Goodkin DE, Priore RL, Wende KE et al Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Mulitple Sclerosis Collaborative Research Group (MSCRG). Mult. Scler. 4, 480-86 (1998). (Pubitemid 29042154)
48. Rudick RA, Goodkin DE, Jacobs LD et al. Impact of interferon β-la on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 49(2), 358-363 (1997). (Pubitemid 27368867)
49. Simon JH, Lull J, Jacobs LD et al. A longtitudinal study of T1 hypointense lesions in relapsing MS. Neurology 55, 185-192 (2000).
50. O'Connor P. The effects of intramuscular interferon β-la in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clin. Ther. 25(11), 2865-2874 (2003). (Pubitemid 37510595)
51. Clanet M, Kappos L, Hartung H-P, Hohlfeld R, European IFNβ-la Dose-Comparison Study Investigators. Interferon β-la in relapsing multiple sclerosis: fouryear extension of the European IFNβ-la Dose-Comparison Study. Mult. Scler. 10, 139-144 (2004). (Pubitemid 38499904)
52. PRISMS (Prevention of Relapses and Disability by Interferon-β-la Subcutaneously in Multiple Sclerosis) Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-la in relapsing MS. Neurology 56, 1628-1636 (2001).
53. Dalton CM, Brex PA, Jenkins R et al Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis, J. Neurol. Neurosurg. Psychiatry 73, 141-147 (2002).
54. Hardmeier M, Wagenpfeil S, Freitag P et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-la. Neurology 64, 236-240 (2005).
55. INFβ Multiple Sclerosis Study Group, University of British Columbia MS-MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon β-lb: experience during the first three years. Neurology 47, 889-894 (1996).
56. European Study Group on Interferon β-lb in Secondary Progressive MS. Placebo-controlled multicenter randomized trial of interferon β-lb in treatment of secondary progressive multiple sclerosis. Lancet 352, 1491-1497 (1998).
57. Rudick RA, Simonian NA, Alam JA et al Incidence and significance of neutralizing antibodies to interferon β-la in multiple sclerosis. Neurology 50, 1266-1272 (1998). (Pubitemid 28240338)
58. Bertolotto A, Malucchi S, Sala A et al. Differential effects of three interferon βs on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J. Neurol. Neurosurg. Psychiatry 73, 148-153 (2002).
59. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon-β therapy. Neurology 65, 33-49 (2005).
60. Francis GS, Rice GPA, Alsop JC, for the PRISMS Study Group. Interferon β-la in MS. Results following development of neutralizing antibodies in PRISMS. Neurology 65, 48-55 (2005). (Pubitemid 40967775)
61. Bertolotto A, Sala A, Malucchi S et al. Biological activity of interferon βs in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J. Neurol. Neurosurg. Psychiatry 75(9), 1294-1299 (2004). (Pubitemid 39141336)
62. Giovannoni G, Goodman A. Neutralizing anti-IFN-β antibodies. How much more evidence do we need to use them in practice? Neurology 65, 6-8 (2005). (Pubitemid 40967766)
63. Sorensen PS, Ross C, Clemmesen KM et al. Clinical importance of neutralizing antibodies against interferon β in patients with relapsing-remitting multiple sclerosis. Lancet 362, 1184-91 (2003). (Pubitemid 37255344)
64. Kappos L, Clanet M, Sandberg-Wollheim M et al. Neutralizing antibodies and efficacy of interferon β-la. A 4-year controlled study. Neurology 65, 40-47 (2005). (Pubitemid 40967774)
65. Ross C, Clemmesen KM, Svenson M et al. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency and route of administration. Danish Multiple Sclerosis Study Group. Ann. Neurol. 48, 706-712 (2000).
66. Hartung H-P, Munschauer F III, Schellekens H. Significance of neutralizing antibodies to interferon β during treatment of multiple sclerosis: expert opinions based on the proceedings of an international consensus conference. Eur. J. Neurol 12, 588-601 (2005). (Pubitemid 41117283)
67. Fischer JS, Priore RL, Jacobs LD et al. Neuropsychological effects of interferon β-la in relapsing multiple sclerosis. Ann. Neurol. 48, 885-892 (2000).
68. Rice GPA, Incorvaia B, Munari L et al. Interferon in relapsing-remitting multiple sclerosis (Cochrane review). In: The Cochrane Library, Issue 3- John Wiley & Sons, Ltd., Chichester, UK (2004).
69. Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis (Cochrane review). In: The Cochrane Library, Issue 1. John Wiley & Sons, Ltd, Chichester, UK (2004).
70. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl. J. Med. 354(9), 899-910 (2006).
71. Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon β-la for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 911-923 (2006).
72. Yousry TA, Habil M, Major EO et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354(9), 924-933 (2006).
73. Calabresi PA, Wilterdink JL, Rogg JM, Mills P, Webb A, Whartenby KA. An open-label trial of combination therapy with interferon β-la and oral methotrexate in MS. Neurology 58, 314-317 (2002). (Pubitemid 34084230)
74. Patti F, Cataldi ML, Nicoletti F, Reggio E, Nicoletti A, Reggio A Combination of cyclophosphamide and interferon-β halts progression in patients with rapidly transitional multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 71(3), 404-407 (2001). (Pubitemid 32772544)
75. Lus G, Romano F, Scuotto A, Accardo C, Cotrufo R. Azathioprine and interferon β (la) in relapsing-remitting multiple sclerosis patients: Increasing efficacy of combined treatment. Euro. Neurology 51(1), 15-20 (2004). (Pubitemid 38041613)
76. Fernández O, Guerrero M, Mayorga C et al. Combination therapy with interferon β-lb and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. J. Neurol 249(8), 1058-1062 (2002). (Pubitemid 35002229)